A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

By Chu Quincy   Forouzesh Bahram   Syed Samira   Mita Monica   Schwartz Garry   Cooper Joshua   Curtright Janet   Rowinsky Eric  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 357-357

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

By Yoo Changhoon   Lee Jeeyun   Rha Sun   Park Kyong   Kim Tae   Kim Yu   Lee Hyo   Lee Kyung   Ahn Jin-Hee  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1602-1608

Springer Publishing Company

Access to resources Recommend Favorite

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

By Paz-Ares Luis  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 729-740

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

By Stroppa Elisa   Bertuzzi Alexia   Comite Gabriele   Mussi Chiara   Lutman Romano   Barbato Alfredo   Santoro Armando  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 834-838

Springer Publishing Company

Access to resources Recommend Favorite

Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases

By Scatena R.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 9, 2000-09 ,pp. : 2159-2165

Informa Healthcare

Access to resources Recommend Favorite